Psychometrics of patient-reported outcomes measurement information system in von Willebrand disease, inherited platelet function disorders, and rare bleeding disorders

Publication date

2024-05

Authors

van Hoorn, Evelien S.
Willems, Sterre P.E.
Al Arashi, Wala
de Moor, Annick S.
van Kwawegen, Calvin B.
Teela, Lorynn
Oude Voshaar, Martijn A.H.
Kremer Hovinga, IdskeISNI 0000000390942394
Schutgens, Roger E GORCID 0000-0002-2762-6033ISNI 000000039036570X
Schols, Saskia E.M.

Editors

Advisors

Supervisors

Document Type

Article

Collections

Open Access logo

License

cc_by

Abstract

Background: Patient-reported outcomes measurement information system (PROMIS) measures can be used to measure patient-reported outcomes. PROMIS measures, including computer adaptive tests (CATs) and short forms, have demonstrated the ability to adequately assess outcomes in patients with hemophilia. It is, however, unclear if PROMIS measures are suitable for patients with von Willebrand disease (VWD), inherited platelet function disorders (IPFDs), and rare bleeding disorders (RBDs). Objectives: To evaluate the feasibility, measurement properties, and relevance of PROMIS measures in adults with VWD, IPFDs, and RBDs. Methods: In this cross-sectional multicenter study, adults with VWD, IPFDs, and RBDs completed 9 PROMIS measures and the Short Form-36 version 2 (SF-36v2) electronically. Feasibility was determined by the number of completed items and floor/ceiling effects. Measurement properties included construct validity based on a multitrait–multimethod analysis and reliability using the reliability coefficient and greatest lower bound. Relevance was evaluated based on comparison with the Dutch general population. Results: In total, 111 patients (median age, 57 years [IQR, 44-67]; 60% VWD, 16% IPFD, 24% RBD) participated. Mean number of items answered varied from 5.3 to 8.7 (range, 4-12) per PROMIS CAT in patients with VWD. Construct validity was supported for all CATs and all instruments had a good reliability (≥0.70). The PROMIS measures had less ceiling effects than the SF-36v2. Conclusion: The PROMIS measures are a feasible, valid, and reliable alternative for the SF-36v2 in patients with primarily nonsevere forms of VWD. The relevance of the selected measures was limited. Additional research is necessary to evaluate the PROMIS measures in adults with IPFDs and RBDs.

Keywords

adult, blood platelet disorders, coagulation protein disorders, feasibility studies, patient-reported outcome measures, von Willebrand diseases, Hematology

Citation

van Hoorn, E S, Willems, S P E, Al Arashi, W, de Moor, A S, van Kwawegen, C B, Teela, L, Oude Voshaar, M A H, Kremer Hovinga, I C L, Schutgens, R E G, Schols, S E M, Leebeek, F W G, Haverman, L, Cnossen, M H, Gouw, S C, Lingsma, H F & SYMPHONY consortium and the Dutch research group for PROMIS implementation in inherited bleeding disorders 2024, 'Psychometrics of patient-reported outcomes measurement information system in von Willebrand disease, inherited platelet function disorders, and rare bleeding disorders', Research and practice in thrombosis and haemostasis, vol. 8, no. 4, 102474. https://doi.org/10.1016/j.rpth.2024.102474